The ANSWER study (NCT04455594), prospectively exploring the efficacy and safety of aumolertinib versus erlotinib or chemotherapy as neoadjuvant therapy for stage IIIA EGFR-mutated NSCLC is currently recruited and expected to provide more clues to ask this question (Liang et al., 2022). Here, EGFR is linked to non-small cell lung carcinoma.